Use of Whole‐Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open‐Label Trial

@article{Sellam2014UseOW,
  title={Use of Whole‐Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open‐Label Trial},
  author={J{\'e}r{\'e}mie Sellam and Sandrine Marion-Thore and Florent Dumont and S{\'e}bastien Jacques and Henri-Jean Garchon and St{\'e}phanie Rouanet and Yassine Taoufik and Houria Hendel-Chavez and Jean Sibilia and Jacques Tebib and Xavier le Lo{\"e}t and Bernard G Combe and Maxime R Dougados and Xavier Mariette and Gilles Chiocchia},
  journal={Arthritis & rheumatology},
  year={2014},
  volume={66 8},
  pages={
          2015-25
        }
}
OBJECTIVE To identify a molecular signature that could be predictive of the clinical response to rituximab (RTX) and elucidate the transcriptomic changes after RTX therapy in patients with rheumatoid arthritis (RA), with the use of whole-blood transcriptomic profiling. METHODS A microarray assay of the whole human genome was performed using RNA from peripheral blood samples obtained before the first cycle of RTX from 68 patients with RA in the SMART study. The transcriptomic profile was also… CONTINUE READING
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-4 of 4 citations